SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools
This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test. We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen te...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical epidemiology 2022-05, Vol.145, p.14-19 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 19 |
|---|---|
| container_issue | |
| container_start_page | 14 |
| container_title | Journal of clinical epidemiology |
| container_volume | 145 |
| creator | Polechová, Jitka Johnson, Kory D. Payne, Pavel Crozier, Alex Beiglböck, Mathias Plevka, Pavel Schernhammer, Eva |
| description | This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test.
We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children.
Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort.
Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic. |
| doi_str_mv | 10.1016/j.jclinepi.2022.01.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8760838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0895435622000087</els_id><sourcerecordid>2621267624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-6d25597837883a3658df9d16a0b60cc4a2f77b28372eed840c1dedaf0612e96a3</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EosvCK1SWuHBJsJ3Edi6I1ar8kSohUeBqOfakdUjsYCcrceMdeEOeBK-2rYALJ0ue33wz33wInVNSUkL5y6EczOg8zK5khLGS0JIQ9gBtqBSyaFpGH6INkW1T1FXDz9CTlAZCqCCieYzOqobUtBVsg75e7T5eFfvwpWA46tlZrP3irsHjBdKS8BzDwVnAHXjoXf7oQ8R5qoXJGWyCX2IY8a8fP3HoEsSDXlzwmYphwrs1LdFpj5O5CWFMT9GjXo8Jnt2-W_T5zcWn_bvi8sPb9_vdZWHqtl0KblnTtEJWQspKV7yRtm8t5Zp0nBhTa9YL0bFcZwBW1sRQC1b3hFMGLdfVFr066c5rN4E1kJfUo5qjm3T8roJ26u-KdzfqOhyUFJzISmaBF7cCMXxb8x3U5JKBcdQewpoU44wyLjirM_r8H3QIa_TZXqayh4YeJbeInygTQ0oR-vtlKFHHPNWg7vJUxzwVoSrnmRvP_7Ry33YXYAZenwDIBz04iCoZB96AdRHMomxw_5vxG2VmtxY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2678351608</pqid></control><display><type>article</type><title>SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Polechová, Jitka ; Johnson, Kory D. ; Payne, Pavel ; Crozier, Alex ; Beiglböck, Mathias ; Plevka, Pavel ; Schernhammer, Eva</creator><creatorcontrib>Polechová, Jitka ; Johnson, Kory D. ; Payne, Pavel ; Crozier, Alex ; Beiglböck, Mathias ; Plevka, Pavel ; Schernhammer, Eva</creatorcontrib><description>This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test.
We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children.
Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort.
Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic.</description><identifier>ISSN: 0895-4356</identifier><identifier>ISSN: 1878-5921</identifier><identifier>EISSN: 1878-5921</identifier><identifier>DOI: 10.1016/j.jclinepi.2022.01.002</identifier><identifier>PMID: 35041972</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antigens ; Asymptomatic ; Austria - epidemiology ; Child ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - epidemiology ; COVID-19 vaccines ; Covid-Series ; Disease control ; Disease transmission ; Epidemics ; Epidemiology ; Genomes ; Humans ; Infections ; Large-scale testing ; Lateral flow device ; Logistics ; Pandemics ; Public health ; Repeat testing ; Respiratory tract ; SARS-CoV-2 ; Schools ; Sensitivity and Specificity ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases ; Viruses</subject><ispartof>Journal of clinical epidemiology, 2022-05, Vol.145, p.14-19</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited May 2022</rights><rights>2022 The Authors. Published by Elsevier Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-6d25597837883a3658df9d16a0b60cc4a2f77b28372eed840c1dedaf0612e96a3</citedby><cites>FETCH-LOGICAL-c499t-6d25597837883a3658df9d16a0b60cc4a2f77b28372eed840c1dedaf0612e96a3</cites><orcidid>0000-0003-0951-3112 ; 0000-0002-2711-9453 ; 0000-0002-7322-2451 ; 0000-0002-4337-9415</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2678351608?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35041972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Polechová, Jitka</creatorcontrib><creatorcontrib>Johnson, Kory D.</creatorcontrib><creatorcontrib>Payne, Pavel</creatorcontrib><creatorcontrib>Crozier, Alex</creatorcontrib><creatorcontrib>Beiglböck, Mathias</creatorcontrib><creatorcontrib>Plevka, Pavel</creatorcontrib><creatorcontrib>Schernhammer, Eva</creatorcontrib><title>SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools</title><title>Journal of clinical epidemiology</title><addtitle>J Clin Epidemiol</addtitle><description>This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test.
We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children.
Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort.
Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic.</description><subject>Antigens</subject><subject>Asymptomatic</subject><subject>Austria - epidemiology</subject><subject>Child</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 vaccines</subject><subject>Covid-Series</subject><subject>Disease control</subject><subject>Disease transmission</subject><subject>Epidemics</subject><subject>Epidemiology</subject><subject>Genomes</subject><subject>Humans</subject><subject>Infections</subject><subject>Large-scale testing</subject><subject>Lateral flow device</subject><subject>Logistics</subject><subject>Pandemics</subject><subject>Public health</subject><subject>Repeat testing</subject><subject>Respiratory tract</subject><subject>SARS-CoV-2</subject><subject>Schools</subject><subject>Sensitivity and Specificity</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><subject>Viruses</subject><issn>0895-4356</issn><issn>1878-5921</issn><issn>1878-5921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc9u1DAQxi0EosvCK1SWuHBJsJ3Edi6I1ar8kSohUeBqOfakdUjsYCcrceMdeEOeBK-2rYALJ0ue33wz33wInVNSUkL5y6EczOg8zK5khLGS0JIQ9gBtqBSyaFpGH6INkW1T1FXDz9CTlAZCqCCieYzOqobUtBVsg75e7T5eFfvwpWA46tlZrP3irsHjBdKS8BzDwVnAHXjoXf7oQ8R5qoXJGWyCX2IY8a8fP3HoEsSDXlzwmYphwrs1LdFpj5O5CWFMT9GjXo8Jnt2-W_T5zcWn_bvi8sPb9_vdZWHqtl0KblnTtEJWQspKV7yRtm8t5Zp0nBhTa9YL0bFcZwBW1sRQC1b3hFMGLdfVFr066c5rN4E1kJfUo5qjm3T8roJ26u-KdzfqOhyUFJzISmaBF7cCMXxb8x3U5JKBcdQewpoU44wyLjirM_r8H3QIa_TZXqayh4YeJbeInygTQ0oR-vtlKFHHPNWg7vJUxzwVoSrnmRvP_7Ry33YXYAZenwDIBz04iCoZB96AdRHMomxw_5vxG2VmtxY</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Polechová, Jitka</creator><creator>Johnson, Kory D.</creator><creator>Payne, Pavel</creator><creator>Crozier, Alex</creator><creator>Beiglböck, Mathias</creator><creator>Plevka, Pavel</creator><creator>Schernhammer, Eva</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>The Authors. Published by Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7T2</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0951-3112</orcidid><orcidid>https://orcid.org/0000-0002-2711-9453</orcidid><orcidid>https://orcid.org/0000-0002-7322-2451</orcidid><orcidid>https://orcid.org/0000-0002-4337-9415</orcidid></search><sort><creationdate>20220501</creationdate><title>SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools</title><author>Polechová, Jitka ; Johnson, Kory D. ; Payne, Pavel ; Crozier, Alex ; Beiglböck, Mathias ; Plevka, Pavel ; Schernhammer, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-6d25597837883a3658df9d16a0b60cc4a2f77b28372eed840c1dedaf0612e96a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Asymptomatic</topic><topic>Austria - epidemiology</topic><topic>Child</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 vaccines</topic><topic>Covid-Series</topic><topic>Disease control</topic><topic>Disease transmission</topic><topic>Epidemics</topic><topic>Epidemiology</topic><topic>Genomes</topic><topic>Humans</topic><topic>Infections</topic><topic>Large-scale testing</topic><topic>Lateral flow device</topic><topic>Logistics</topic><topic>Pandemics</topic><topic>Public health</topic><topic>Repeat testing</topic><topic>Respiratory tract</topic><topic>SARS-CoV-2</topic><topic>Schools</topic><topic>Sensitivity and Specificity</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Polechová, Jitka</creatorcontrib><creatorcontrib>Johnson, Kory D.</creatorcontrib><creatorcontrib>Payne, Pavel</creatorcontrib><creatorcontrib>Crozier, Alex</creatorcontrib><creatorcontrib>Beiglböck, Mathias</creatorcontrib><creatorcontrib>Plevka, Pavel</creatorcontrib><creatorcontrib>Schernhammer, Eva</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Polechová, Jitka</au><au>Johnson, Kory D.</au><au>Payne, Pavel</au><au>Crozier, Alex</au><au>Beiglböck, Mathias</au><au>Plevka, Pavel</au><au>Schernhammer, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools</atitle><jtitle>Journal of clinical epidemiology</jtitle><addtitle>J Clin Epidemiol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>145</volume><spage>14</spage><epage>19</epage><pages>14-19</pages><issn>0895-4356</issn><issn>1878-5921</issn><eissn>1878-5921</eissn><abstract>This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test.
We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children.
Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort.
Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35041972</pmid><doi>10.1016/j.jclinepi.2022.01.002</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0951-3112</orcidid><orcidid>https://orcid.org/0000-0002-2711-9453</orcidid><orcidid>https://orcid.org/0000-0002-7322-2451</orcidid><orcidid>https://orcid.org/0000-0002-4337-9415</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-4356 |
| ispartof | Journal of clinical epidemiology, 2022-05, Vol.145, p.14-19 |
| issn | 0895-4356 1878-5921 1878-5921 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8760838 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Antigens Asymptomatic Austria - epidemiology Child Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 vaccines Covid-Series Disease control Disease transmission Epidemics Epidemiology Genomes Humans Infections Large-scale testing Lateral flow device Logistics Pandemics Public health Repeat testing Respiratory tract SARS-CoV-2 Schools Sensitivity and Specificity Severe acute respiratory syndrome coronavirus 2 Viral diseases Viruses |
| title | SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A17%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SARS-CoV-2%20rapid%20antigen%20tests%20provide%20benefits%20for%20epidemic%20control%20%E2%80%93%20observations%20from%20Austrian%20schools&rft.jtitle=Journal%20of%20clinical%20epidemiology&rft.au=Polechov%C3%A1,%20Jitka&rft.date=2022-05-01&rft.volume=145&rft.spage=14&rft.epage=19&rft.pages=14-19&rft.issn=0895-4356&rft.eissn=1878-5921&rft_id=info:doi/10.1016/j.jclinepi.2022.01.002&rft_dat=%3Cproquest_pubme%3E2621267624%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2678351608&rft_id=info:pmid/35041972&rft_els_id=S0895435622000087&rfr_iscdi=true |